Disability Accommodations for Individuals with Chronic Fatigue Syndrome

Introduction to CFS and Disability Criteria

• The American Medical Association and other organizations recognize that CFS (also called ME/CFS) can cause significant functional limitations that meet disability criteria for parking accommodations, including severe fatigue and post-exertional malaise, limited walking capacity, and energy conservation needs 1

Evaluation and Documentation

• Healthcare providers should evaluate the functional impact of CFS on the patient's ability to walk distances typically required in parking situations, as well as document the severity and duration of symptom flares after physical exertion, and assess how energy conservation through reduced walking distances would benefit the patient's overall function and quality of life 1

Rationale for Providing Handicap Placards

• The Centers for Disease Control and Prevention and other health organizations support the provision of handicap placards to CFS patients, as reducing physical exertion through closer parking aligns with recommended pacing strategies to prevent post-exertional malaise, and handicap placards support the energy conservation techniques recommended by clinical guidelines, which helps prevent symptom exacerbation, a critical aspect of CFS management 1

Application and Renewal Process

• Patients should obtain medical certification from their healthcare provider, complete the required state form, and submit the application through their state's Department of Motor Vehicles or equivalent agency, and be aware of expiration dates and renewal requirements, which vary by state 1

Accommodation Considerations

• The National Institute of Neurological Disorders and Stroke and other organizations recognize that CFS is an invisible disability, and patients may need to educate others about their legitimate need for accommodation, and that even if symptoms fluctuate, the consistent need to conserve energy and prevent post-exertional malaise justifies the accommodation 1

Management of ME/CFS and Long COVID

• A symptom-targeted approach combining pacing strategies, anti-inflammatory interventions, and symptom-specific medications offers the best outcomes for reducing morbidity, mortality, and improving quality of life in patients with ME/CFS and Long COVID, as recommended by the American College of Microbiology 2
• Implement cognitive and physical pacing to prevent post-exertional malaise (PEM), and use heart rate monitoring tools to establish baseline and avoid exceeding energy limits, with strong evidence from the American College of Microbiology 2
• Schedule pre-emptive rest periods before engaging in activities to prevent PEM, as suggested by the American College of Microbiology 2
• Avoid exercise for patients with PEM, as physical activity worsens symptoms in 75% of long COVID patients, according to the American College of Microbiology 2

Pharmacological Options

• The following table summarizes pharmacological options for ME/CFS and Long COVID:

• Low-dose naltrexone (LDN) is effective for neuroinflammation, pain, fatigue, and neurological symptoms, starting at 1.5 mg daily and increasing by 1.5 mg every 2-4 weeks to a maximum of 6 mg daily, with moderate evidence from the American College of Microbiology 2
• Beta-blockers, such as propranolol 10-20 mg up to 4 times daily, can be used to manage symptoms, as recommended by the American College of Microbiology 2
• Coenzyme Q10 200 mg daily can be used for mitochondrial support, with moderate evidence from the American College of Microbiology 2
• D-ribose can be used for energy production and ATP enhancement, as suggested by the American College of Microbiology 2
• Alpha-lipoic acid 600 mg twice daily can be used to treat autonomic neuropathy and oxidative stress, with moderate evidence from the American College of Microbiology 2
• N-acetylcysteine 500-1800 mg divided into 2-3 doses on an empty stomach can be used to treat oxidative stress, as recommended by the American College of Microbiology 2

Non-Pharmacological Options

• Increase salt intake to 10-12g/day and fluid intake to 2-3L/day to manage autonomic dysfunction, with moderate evidence from the American College of Microbiology 2
• Use compression stockings (20-40 mmHg) focusing on the abdomen and legs to manage orthostatic hypotension, as suggested by the American College of Microbiology 2
• Implement cognitive pacing strategies to manage cognitive dysfunction, with strong evidence from the American College of Microbiology 2
• Stimulant medications, such as methylphenidate 20 mg/day divided into two 10 mg doses, can be used to treat cognitive dysfunction, as recommended by the American Heart Association 4
• Melatonin 3-5 mg four-six hours before desired bedtime can be used to treat insomnia, with moderate evidence from the American College of Microbiology 2
• Low-dose doxepin (3 mg) or trazodone (50 mg) nightly can be used to treat insomnia, as suggested by the American College of Microbiology 2
• Probiotics have shown promise in alleviating both gastrointestinal and non-gastrointestinal symptoms, with moderate evidence from the American College of Microbiology 2

Treatment Approach

• First-line approach: implement pacing strategies and energy conservation, start LDN 1.5 mg daily, add CoQ10 and D-ribose supplements, and address autonomic dysfunction with salt/fluid increase and compression garments, with strong evidence from the American College of Microbiology 2
• If inadequate response after 4-6 weeks, increase LDN dose gradually, add symptom-specific medications based on predominant symptoms, and consider antihistamines if mast cell activation is suspected, as suggested by the American College of Microbiology 2
• Regular assessment of fatigue severity, impact, and coping strategies is recommended, incorporating single-item instruments as screening tools (e.g., BRAF-NRS) and supplementing with multidimensional assessments if significant fatigue is identified, as suggested by the European League Against Rheumatism 5
• Aerobic exercise has strong evidence for reducing fatigue in MS patients, increasing aerobic capacity, improving functional performance, and reducing depressive symptoms, as reported by the European League Against Rheumatism and the American College of Sports Medicine 5, 6
• Structured psychoeducational programs show significant benefits for MS fatigue, including cognitive behavioral therapy for fatigue management, energy conservation techniques, cognitive pacing strategies, sleep hygiene training, and stress management, according to the European League Against Rheumatism 5
• Respiratory muscle training (RMT) has shown improvements in respiratory muscle strength, dyspnea, functional performance, and quality of life, as reported by the European Respiratory Society 7
• Implement cognitive pacing strategies, energy conservation techniques, and a gradually incremental approach to building activity tolerance, as suggested by the European League Against Rheumatism 5
• Address reversible contributing factors to fatigue, including anemia, sleep disturbances, pain, and mood disorders, as advised by the American Society of Clinical Oncology and the European Crohn's and Colitis Organisation 8, 9
• The initial approach should begin with a tailored physical activity program and structured psychoeducational intervention, addressing reversible contributing factors, as recommended by the European League Against Rheumatism 5
• If there is an inadequate response after 4-6 weeks, pharmacological therapy should be added, starting with amantadine, and monitoring for side effects and efficacy, according to the European League Against Rheumatism 5
• Individualize dosing based on severity of symptoms and response to treatment, considering the risks of long-term IV therapy, including infection and electrolyte imbalances, as warned by the Infectious Diseases Society of America and Centers for Disease Control and Prevention 10
• Non-pharmacological options like increasing salt and fluid intake, using compression stockings, and addressing sleep disorders can also be beneficial in managing long COVID symptoms, with moderate evidence supporting the importance of sleep management, as reported by the American College of Microbiology 2, 10